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osting by EAbstract A high performance thin layer chromatography (HPTLC) method was developed and val-
idated for determination of two anti-asthmatic drugs, salmeterol xinafoate and ﬂuticasone propio-
nate in co-formulations. Study was performed on pre-coated silica gel HPTLC plates using
n-hexane:ethyl acetate:acetic acid (5:10:0.2) as a mobile phase. A TLC scanner set at 250 nm was used
for direct evaluation of the chromatograms in reﬂectance/absorbance mode. Method was validated
according to ICH guidelines. Determination coefﬁcients of calibration curves were found 0.9977
and 0.9936 in the ranges 100–1000 and 200–2000 ng band1 for salmeterol and ﬂuticasone, respec-
tively. Method had an accuracy of 99.5% for salmeterol and 102.01% for ﬂuticasone. Method had
the potential to determine these drugs simultaneously from dosage forms without any interference.
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lsevier1. Introduction
Salmeterol (Fig. 1a) is a long-acting and highly selective b2 ago-
nist formulated as its 1-hydroxy-2-napthoate (xinafoate) salt
used in the treatment of asthma and chronic obstructive pul-
monary disease (Michael et al., 2000; Murnane et al., 2006).
Fluticasone propionate (Fig. 1b) is a neutral, highly potent tri-
ﬂuorinated corticosteroid based on the androstane nucleus. It
is effective in treatments of asthma and allergic rhinitis because
of its anti-inﬂammatory activity (Laugher et al., 1999; Krish-
naswami et al., 2000). These two drugs are formulated as dry
powder inhalers or pressurized metered dose inhalers individu-
ally or in combined formulation (Ringdal et al., 2007).
Validated assays have been reported for each drug individ-
ually. For analysis of salmeterol xinafoate from body matrices,
liquid chromatography with MS (You-xuan et al., 2003),
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Figure 1 Chemical structures of salmeterol xinafoate (a) and
ﬂuticasone propionate (b).
154 L. Kasaye et al.MS/MS (Lehner et al., 2004) and ﬂuorescence detection
(Colthup et al., 2006) were reported. Spectrophotometric tech-
niques have been reported for the determination of salmeterol
xinafoate in its dosage forms (Chowdary and Rao, 1998, 1999;
Reddy et al., 2000). Liquid chromatography coupled with
APCI-MS (Yuan et al., 2001), and tandem mass spectrometers
have been reported for the determination of ﬂuticasone propi-
onate in human plasma (Laugher et al., 1999; Krishnaswami
et al., 2000; Vannecke et al., 2000).
There is a need for an assaymethod that permits simultaneous
quantiﬁcation of salmeterol xinafoate and ﬂuticasone propio-
nate. AnHPLCmethodwas reported for the concurrent analysis
of these drugs in pressurized metered dose inhalers (Murnane
et al., 2006). However, the detection in this method was done at
228 nmthat is not free from interferences fromsolvents andother
components. Moreover, the method was not validated for deter-
mination of these drugs in the powder for inhalers.
The aim of this work was to develop and validate a simple,
rapid, selective and quite sensitive HPTLC assay method for
simultaneous determination of salmeterol xinafoate and ﬂuti-
casone propionate in bulk powders and dry powder inhalers.
In addition, the method will be inexpensive and not requires
certain types of stationary phases. Thus, it can represent an-
other good alternative for the already existing HPLC methods
especially that the detectors used for these methods are not
present in most of the laboratories.
2. Experimental
2.1. Materials
Salmeterol xinafoate and ﬂuticasone propionate working refer-
ence standards (Glaxowellcome, UK), analytical grade n-hex-
ane (BDH, England), HPLC grade ethyl acetate (BDH,
England), acetic acid (Fluka, Germany) and HPLC grade
methanol (Sigma–Aldrich, Germany), were all obtained from
Drug Administration and Control Authority of Ethiopia.
The dosage forms (Seretide Accuhaler 100/50, Seretide Accu-
haler 250/50 and Seretide Accuhaler 500/50) were all pur-
chased from retail out lets (Addis Ababa, Ethiopia).
2.2. Instrumentation
Microsyringe (Linomat syringe 659.004, Hamilton-Bonaduz
schweiz, Camag, Switzerland), pre-coated silica gel 60 F-254
glass plates (10 · 10 cmwith 200 lm, thicknessHPTLC;Merck,
Germany), linomat 5 applicator (Camag, Muttenz, Switzer-
land), twin trough chamber 20 · 10 cm (Camag, Muttenz,
Switzerland), saturation pad (Camag, Muttenz, Switzerland),UV chamber (Camag, Muttenz, Switzerland), TLC scanner
III (Camag, Muttenz, Switzerland), winCATS version 1.4.0
software (Camag, Muttenz, Switzerland) were used in this
study. Microsoft excel was also used to treat data statistically.
2.3. Standard solutions
Stock standard solutions were prepared by dissolving 10 mg of
salmeterol xinafoate and 20 mg of ﬂuticasone propionate in
100 ml methanol to obtain concentration of 100 lg ml1 and
200 lg ml1 of salmeterol xinafoate and ﬂuticasone propio-
nate, respectively. Ten different concentration levels of work-
ing standard solutions were freshly prepared by diluting
suitable volumes of the stock standard solution to 25 ml with
methanol in appropriate volumetric ﬂasks.
2.4. Sample solutions
2.4.1. Single-dose analysis
The contents of one blister were transferred quantitatively into
25 ml volumetric ﬂask and the inner sides of the blister were
washed with methanol three times. The volume was made up to
about 20 ml with methanol and the contents were dissolved with
the aid of shaking and sonication for about 10 min, then diluted
to volume with the same solvent and ﬁltered through 0.45 lm
nylon syringe ﬁlters. Working sample solutions were freshly
prepared by diluting suitable volumes of the stock sample solu-
tion to 25 ml with methanol in appropriate volumetric ﬂasks.
2.4.2. Multi-dose analysis
The contents of ﬁve blisters were quantitatively transferred into
100 ml volumetric ﬂask. The volume was made up to about
80 ml with methanol and the contents were dissolved with the
aid of shaking and sonication for about 10 min, then diluted
to volume with the same solvent and ﬁltered through 0.45 lm
nylon syringe ﬁlters. Working sample solutions were freshly
prepared by diluting suitable volumes of the stock sample solu-
tion to 25 ml with methanol in appropriate volumetric ﬂasks.
2.5. Chromatographic conditions
Sample was applied to the plate 10 mm from the bottom and
10 mm from the side edges in the form of band or streak with
band length of 6 mm. The mobile phase consisted of n-hex-
ane:ethyl acetate:acetic acid (5:10:0.2, v/v/v) and 15 ml of the
mobile phase was used in each chromatographic run. Ascend-
ing development technique was carried out in a twin trough
chamber. The optimized chamber saturation time for the mo-
bile phase was 25 min at room temperature (20 ± 2 C) that
was assisted by saturation pad. The distance covered by the
solvent front was 8 cm, which took about 15 min. The spots
were scanned using the TLC scanner 3 in the reﬂectance/absor-
bance mode at 250 nm and all measurements were operated by
winCATS software. Concentrations of the separated com-
pounds were determined from the intensity of reﬂected light
and peak areas were used for comparison.
2.6. Method validation
The method was validated in compliance with ICH guidelines
(ICH 1994, 1996). The following parameters were used for val-
idation of the developed method.
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Linear relationship between peak area and concentration of
the drugs were evaluated over the range of concentrations ex-
pressed in ng band1 by making ﬁve measurements at 10 con-
centration levels in the range of 100–1000 ng band1 for
salmeterol xinafoate and 200–2000 ng band1 for ﬂuticasone
propionate, respectively.
2.6.2. Recovery studies
Recovery studies were carried out by spiking four different
known amounts of the standard substances to the drug prod-
uct (standard addition method). Hence, 125, 250, 375 and
500 ng band1 of salmeterol xinafoate and 250, 500, 750 and
1000 ng band1 of ﬂuticasone propionate were spiked to the
dosage form that contained 250 and 500 ng band1 of salme-
terol xinafoate and ﬂuticasone propionate, respectively, after
sample dilution.
2.6.3. Precision
Precision of the developed method was studied by considering
intra-day precision, inter-day precision and variation between
analysts.
2.6.4. Limits of detection and quantiﬁcation
Determination of the detection and quantiﬁcation limits was
performed based on the standard deviations of the blank re-
sponses and the slope of the least square line parameters.
2.6.5. Speciﬁcity
Peak purity of both salmeterol xinafoate and ﬂuticasone pro-
pionate was assessed to evaluate the speciﬁcity of the method.
The spots of dosage forms were scanned at three different lev-
els, i.e., peak start (S), peak apex (M), and peak end (E) posi-
tions. Correlation coefﬁcients of these spectra were calculated.
The spectra of dosage form and reference standards were also
compared for both studied drugs.
2.6.6. Robustness
Composition of the mobile phase, volume of the mobile phase,
time from spotting to development and time from development
to scanning was involved in this study. The composition and
volume of the mobile phase were varied in the range of
±10% of the used optimized conditions. Time variations were
varied from the optimized times in the range of ±20% (Habte
et al., 2009). The effect of these changes on both the Rf values
and peak areas were evaluated by calculating the relative stan-
dard deviations (RSD) for each parameter.
3. Results and discussions
3.1. Method optimization for the HPTLC-densitometric
measurements
Several trials were made by using different solvent systems
containing non-polar solvents, relatively polar solvents and
acetic acid. The use of acetic acid is mandatory to elute
salmeterol from the site of application due to the fact that it
is weakly basic and highly interacting with the stationery
phase, especially the unreacted silanol groups of silica gel
(Murnane et al., 2006; Capka and Carter, 2007). Among the
different mobile phase combinations tested n-hexane:ethyl ace-
tate:acetic acid (5:10:0.2) gave better resolution and sharperpeaks with Rf values of 0.4 ± 0.04 and 0.6 ± 0.03 for salme-
terol xinafoate and ﬂuticasone propionate, respectively.
Fig. 2 shows the HPTLC densitogram of the mixture using
the optimal conditions.
3.2. Method validation
3.2.1. Linearity
Peak areas were found to have good linear relationship with
the concentration than the peak heights. For ﬂuticasone propi-
onate, the r2 was found 0.9936, and for salmeterol xinafoate, the
r2 was 0.9977. Calibration graphs were constructed in the
ranges of 100–1000 ng band1 for salmeterol xinafoate and
200–2000 ng band1 for ﬂuticasone propionate. The correla-
tion coefﬁcients, y-intercepts and slopes of the regression
lines of the two compounds were calculated and presented in
Table 1.
3.2.2. Precision studies
Repeatability and intermediate precision of the developed
method were expressed in terms of coefﬁcients of variation
(CV) of the peak area (Murnane et al., 2006; Sathe and Bari,
2007). The results showed that intra- and inter-day variation
of the results at ﬁve different concentration levels of 300–
700 ng spot1 for salmeterol xinafoate and 600–1400 ng spot1
for ﬂuticasone propionate were within the acceptable range.
The coefﬁcients of variation for both the inter-day and intra-
day precision of the method was found to be less than 4% for
both drugs (Table 2). The dosage forms were also analyzed by
three different analysts within the same day and the results re-
vealed that there is good intermediate precision between analysts
(Table 3) with coefﬁcients of variation of 0.74 and 0.70 for
salmeterol xinafoate and ﬂuticasone propionate, respectively.
3.2.3. Accuracy/recovery studies
The percentage recovery at four levels (Argekar et al., 1996), in
the range from 250 to 750 ng band1 for salmetrol xinafoate
and from 500 to 1500 ng band1 for ﬂuticasone propionate
were studied and found to be satisfactory (Table 4). For ﬂuti-
casone propionate, the recoveries were found between 97.1%
and 103.5% and for salmeterol xinafoate the recoveries were
found between 99.2% and 101.7%.
3.2.4. Limits of detection and quantitation
The limits of detection and quantiﬁcation of the developed
method were calculated using 3a/S and 10a/S phenomena
for the limits of detection and quantiﬁcation, respectively
(Eric-Jovanovic et al., 1998), where a is the standard devia-
tion of the y-intercepts and S is the slope of the calibration
curve. The limits of detection and quantiﬁcation (Table 1)
were found to be 65.68 ng band1 and 199.033 ng band1,
respectively, for ﬂuticasone propionate. For salmeterol xin-
afoate, were found 33.53 ng band1 and 101.61 ng band1,
respectively.
3.2.5. Speciﬁcity
The peak purity test of ﬂuticasone propionate and salmeterol
xinafoate spots were assessed by comparing their respective
spectra at peak start, peak apex and peak end positions of
the spot (Sathe and Bari, 2007). The results of spectral com-
parison for salmeterol xinafoate were found to be 0.9998 and
0.9998 at peak start–peak apex and at peak apex–peak end,
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Figure 2 Typical densitogram of salmeterol xinafoate (1) and ﬂuticasone propionate (2) spots of the reference standards with back
ground noise correction.
Table 1 Summary of linear regression data for calibration curves using peak areas.
Parameters Fluticasone propionate Salmeterol xinafoate
Linearity range 200–2000 ng band1 100–1000 ng band1
Linear regression equation y= 5.2956x+ 1336.9 y= 6.3301x  45.596
Slope ± SD 5.2956 ± 0.177 6.3301 ± 0.197
Intercept ± SD 1336.9 ± 105.3662 45.596 ± 64.32
Correlation coeﬃcient (r) 0.9968 0.9989
Determination coeﬃcient (r2) 0.9936 0.9977
Limit of detection (LOD) 65.681 33.532
Limit of quantiﬁcation (LOQ) 199.033 101.611
Table 2 Intra- and inter-day precision for salmeterol xinafoate and ﬂuticasone propionate.
Compound Amount (ng band1) Intra-day precision (n= 5) Inter-day precision (n= 5)
Mean peak area SD CVa Mean peak area SD CVa
Salmeterol xinafoate 300 1874.5 16.7 0.9 1800 69.6 3.9
400 2566.0 65.9 2.6 2517.7 42.7 1.7
500 3384.9 96.9 2.9 3317.3 58.6 1.7
600 3925.0 99.5 2.5 3819.1 98.3 2.6
700 4483.5 167.3 3.7 4427.4 55.2 1.2
Fluticasone propionate 600 4631.7 102.5 2.2 4619.9 79.6 1.7
800 5811.7 87.6 1.5 5781.9 65.1 1.1
1000 7140.4 94 1.3 7065.7 106.7 1.5
1200 8048.9 124.5 1.5 7853.5 172.3 2.0
1400 9075.8 136.4 1.5 8882.9 176.6 1.9
a Coefﬁcient of variation.
Table 3 Results for the study of variation between three different analysts.
Analyst Salmeterol xinafoate Fluticasone propionate
Mean peak area (n= 6) SD CV1
a Mean peak area (n= 6) SD CV1
a
1 3765.7 54.1 1.4 5709.9 82.4 1.4
2 3748.8 57.5 1.5 5757.6 65 1.1
3 3711.2 62.4 1.7 5789.8 78.4 1.3
CV2
b 0.74 0.70
a CV1 is the coefﬁcient of variation for six determinations of the same analyst for each substance.
b CV2 is the coefﬁcient of variation between the three analysts for each substance.
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Table 4 Recovery study of the method (using the standard addition method) for salmeterol xinafoate and ﬂuticasone propionate
(n= 6 for both drugs).
Number of levels Salmeterol xinafoate Fluticasone propionate
Initial amount
(ng band1)
Amount
added (mg)
Amount added
(ng band1)
% Recovery Initial amount
(ng band1)
Amount
added (mg)
Amount
added (ng band1)
% Recovery
1 250 0.125 125 99.2 500 0.250 250 103.5
2 250 0.250 250 99.5 500 0.500 500 100.3
3 250 0.375 375 101.7 500 0.750 750 97.7
4 250 0.500 500 99.2 500 1.000 1000 100.9
Accuracy % 99.5 102.01
HPTLC-densitometric method for simultaneous determination of salmeterol xinafoate 157respectively. Similarly, for ﬂuticasone propionate the results
were 0.9997 and 0.9996. The closeness of peak purity values
to 1 indicates that the spots were only attributed to a single
compound. Good correlation (r= 0.9995 and 0.9996) was
also obtained between standard and sample spectra of ﬂutica-
sone propionate and salmeterol xinafoate, respectively. The
UV spectra comparison of the spots of the standards and
dosage forms for the study substances were presented in
Fig. 3.
3.2.6. Robustness
The standard deviations of peak areas were calculated for the
aforementioned four parameters (variation in composition of
the mobile phase, volume of the mobile phase, time from spot-
ting to development and time from development to scanning)
and coefﬁcients of variation were found to be less than 2.5%
in all cases as shown in Table 5. The low CV values, indicate
the robustness of the method.0.0
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Spectra com
Figure 3 UV spectra comparison of the spots of the standards (1) an
propionate (F).
Table 5 Robustness study for the developed method (n= 5).
Parameter studied Salmet
SDa
Composition of mobile phase 130.4
Volume of mobile phase 127.8
Time from spotting to development (5–60 min) 55.29
Time from development to scanning (5–60 min) 40.9
a SD and CV were calculated from the peak areas of densitograms.3.3. Analysis of commercial dosage forms
The commercial dosage forms, Sereretide Accuhaler 100/50,
250/50 and 500/50 have been analyzed using the developed
method. Two approaches were employed in this study, sin-
gle-dose analysis and multi-dose analysis due to the great var-
iation in the inhaler blisters content. In the case of single-dose
analysis, the content of single blister was taken whereas in the
case of multi-dose analysis the contents of ﬁve blisters were ta-
ken quantitatively. In general acceptable results were obtained
for both drugs and were in good agreement with the label
claims. The results of the commercial dosage form analysis
have been presented in Table 6.
3.4. Sample solution stability study
Sample solution was prepared and was kept at room tempera-
ture (20 ± 2 C) on a shelf protected from direct light. The0.0
10.0
20.0
30.0
60.0
70.0
80.0
[ AU ]
100.0
50.0
40.0
[ nm ] 400.0
parison
1(S)
2(S)
1(F)
2(F)
d dosage forms (2) for salmeterol xinafoate (S) and for ﬂuticasone
erol xinafoate Fluticasone propionate
CVa SDa CVa
1.49 358.9 2.3
1.46 344.3 2.21
0.63 256.8 1.65
1.1 22.2 0.40
Table 6 Assay results of the commercial dosage forms (n= 6).
Methods Parameters Seretide Acchaler 100/50 Seretide Acchaler 250/50 Seretide Acchaler 500/50
Salmeterol
xinafoate
Fluticasone
propionate
Salmeterol
xinafoate
Fluticasone
propionate
Salmeterol
xinafoate
Fluticasone
propionate
SDAa Content (%) 97.9 ± 4.3 105.6 ± 1.1 100.4 ± 3.3 100.4 ± 2.6 96.18 ± 2.2 105.64 ± 0.11
CVc 4.39 1.03 1.33 2.41 2.3 0.107
MDAb Content (%) (n= 5) 101.0 ± 1.5 105.1 ± 0.29 104.3 ± 0.93 105.3 ± 1.9 97.17 ± 2.7 108.1 ± 0.72
CVc 1.43 2.75 0.925 1.76 2.74 0.667
Average Content (%) 99.4 ± 2.2 105.3 ± 0.34 100.4 ± 0.007 106.3 ± 1.5 96.67 ± 0.7 106.87 ± 1.74
CVc 2.24 0.33 0.007 1.37 0.72 1.63
a SDA: single-dose analysis.
b MDA: multi-dose analysis (n= 5).
c CV: coefﬁcient of variation.
Table 7 Solution stability study.
Time of analysis Salmeterol xinafoate Fluticasone propionate**
Average peak area (n= 6) ± SD CVa Average peak area (n= 6) ± SD CVa
20 min 3828.67 ± 114.7 2.03 5615.95 ± 60.3 2.17
3 h 3795.11 ± 52.0 2.87 5742.12 ± 101.9 0.99
8 h 3830.88 ± 52.2 0.95 5524.711 ± 36.2 0.95
24 h 3807.87 ± 35.84 1.01 5498.48 ± 38.7 0.65
4 days 3543.85 ± 109.3 1.27 5266.6 ± 48.5 1.90
12 days 2974.7 ± 67.3 1.51 5263.12 ± 57.9 1.20
** Multi dose analysis.
a CV: coefﬁcient of variation.
158 L. Kasaye et al.solution was analyzed after 20 min, 3 h, 8 h, 24 h, 4 days and
12 days. Because of the time needed for sonication and ﬁltra-
tion, the fastest possible analysis was carried out within
20 min and hence results of the remaining analysis times were
compared with it. The average peak areas and the CV values
are presented in Table 7. The average peak areas of ﬂuticasone
propionate were signiﬁcantly varied from the reference time
(p= 0.05, t stat. = 4.73, n= 6) after 24 h and for salmeterol
xinafoate after 4 days of sample preparation (p= 0.05, t
stat. = 5.12, n= 6). Therefore, in order to decrease systematic
errors because of test solution instability, the analysis should
be carried out within 24 h of sample preparation.4. Conclusion
The developed HPTLC/densitometric method was found to be
simple, rapid, selective, quite sensitive and suitable for simulta-
neous determination of salmeterol xinafoate and ﬂuticasone
propionate in three different strengths of Seretide Accuhaler.
Statistical analysis proved that the method is repeatable, accu-
rate and speciﬁc for the analysis of salmetrol xinafoate and ﬂu-
ticasone propionate. The method can minimize the cost of
reagents and time for analysis. It also utilized the merit of
applying several sample spots on HPTLC plate, which may
be more advantageous for regulatory quality control laborato-
ries especially to facilitate the post-marketing surveillance pro-
gram. In addition, the method is inexpensive and not requires
certain types of stationary phases. Thus, it can represent an-
other good alternative for the already existing HPLC methods
especially those using certain types of detectors which are not
present in most of the laboratories.References
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